The value of clinical trial data
Clinical trial data represents years of research worth hundreds of millions of dollars. It includes patient data (personal and medical data protected under GDPR), efficacy and safety results, study protocols and randomization, pharmacokinetic and pharmacodynamic data, and monitor and auditor reports. Loss or manipulation of this data can delay drug registration by years. Patient data breach violates GDPR with penalties up to EUR 20M. APT groups know these data have enormous value for both competitors and dark web markets.
Threats to clinical data
Attacks on EDC systems
Electronic Data Capture (Medidata Rave, Oracle Clinical, Veeva) — central repositories of clinical data. EDC compromise gives access to complete study data.
Phishing targeting investigators and monitors
Investigators at clinical sites rarely undergo cybersecurity training. Attacks impersonating study sponsors or ethics committees.
Threats at research sites
Hospitals conducting clinical trials often have weak IT security. Clinical data can be threatened by a ransomware attack on the hospital.
Unsafe data transfer
Transferring data between CROs, sponsors, central laboratories, and regulators — every transfer is a potential leak point.
Technical safeguards
End-to-end encryption — clinical data encrypted at rest (AES-256) and in transit (TLS 1.3). Keys managed by HSM (Hardware Security Module).
RBAC access control — need-to-know basis. Investigators see only their patients’ data, monitors — only assigned sites, CROs — only commissioned studies.
DLP for clinical data — rules preventing patient data from being sent via email, copied to USB, or uploaded to unauthorized clouds.
Monitoring and audit trail — every clinical data access logged with date, user, and action. Compliance with 21 CFR Part 11 and GCP requirements.
Secure analytical environment — Virtual Desktop Infrastructure (VDI) for biostatisticians — data never leaves the controlled environment.
Regulatory requirements and compliance
GCP (Good Clinical Practice) — requires protection of patient data confidentiality and study data integrity.
21 CFR Part 11 / EU Annex 11 — electronic records and signatures must be secured with access control, audit trail, and system validation.
GDPR — clinical trial patient data is a special category of personal data. Requires DPIA, pseudonymization, and data minimization.
NIS2 — companies conducting clinical trials as essential entities must manage cyber risk and report incidents.
Cybersecurity for Your Industry
Learn more about cybersecurity in your industry:
Why this matters for organizations
Clinical trial data is among the most valuable pharma assets. How to protect it from cyberattacks and meet regulatory requirements? In the context of growing cyber threats and tightening regulations (NIS2, DORA), organizations must proactively manage this security area. Failure to implement adequate safeguards can lead to data breaches, financial penalties, and reputational damage.
Best practices for implementation
Effective implementation requires several key steps:
- Risk assessment and inventory — identify assets, threats, and vulnerabilities specific to your organization.
- Policy development — document requirements, roles, and responsibilities.
- Technical controls — deploy tools and configurations proportionate to identified risks.
- Training and awareness — engage employees in protecting organizational security.
- Monitoring and continuous improvement — regularly verify effectiveness and adapt to the evolving threat landscape.
Related topics
See also:
